Islet-intrinsic effects of CFTR mutation
| Autor: | Neville H. McClenaghan, Catriona Kelly, Fiona N. Manderson Koivula, Alan G.S. Harper |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Endocrinology Diabetes and Metabolism Population Cystic Fibrosis Transmembrane Conductance Regulator 030209 endocrinology & metabolism Review Cystic fibrosis 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Insulin-Secreting Cells medicine Internal Medicine Glucose homeostasis Animals Humans CFTR education education.field_of_study biology Insulin Diabetes Beta cells Correction medicine.disease Cystic fibrosis transmembrane conductance regulator 3. Good health 030104 developmental biology medicine.anatomical_structure Endocrinology Mutation biology.protein ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Beta cell Pancreas Endocrine |
| Zdroj: | Diabetologia |
| ISSN: | 1432-0428 0012-186X |
| Popis: | Cystic fibrosis-related diabetes (CFRD) is the most significant extra-pulmonary comorbidity in cystic fibrosis (CF) patients, and accelerates lung decline. In addition to the traditional view that CFRD is a consequence of fibrotic destruction of the pancreas as a whole, emerging evidence may implicate a role for cystic fibrosis transmembrane-conductance regulator (CFTR) in the regulation of insulin secretion from the pancreatic islet. Impaired first-phase insulin responses and glucose homeostasis have also been reported in CF patients. CFTR expression in both human and mouse beta cells has been confirmed, and recent studies have shown differences in endocrine pancreatic morphology from birth in CF. Recent experimental evidence suggests that functional CFTR channels are required for insulin exocytosis and the regulation of membrane potential in the pancreatic beta cell, which may account for the impairments in insulin secretion observed in many CF patients. These novel insights suggest that the pathogenesis of CFRD is more complicated than originally thought, with implications for diabetes treatment and screening in the CF population. This review summarises recent emerging evidence in support of a primary role for endocrine pancreatic dysfunction in the development of CFRD. Summary • CF is an autosomal recessive disorder caused by mutations in the CFTR gene • The vast majority of morbidity and mortality in CF results from lung disease. However CFRD is the largest extra-pulmonary co-morbidity and rapidly accelerates lung decline • Recent experimental evidence shows that functional CFTR channels are required for normal patterns of first phase insulin secretion from the pancreatic beta cell • Current clinical recommendations suggest that insulin is more effective than oral glucose-lowering drugs for the treatment of CFRD. However, the emergence of CFTR corrector and potentiator drugs may offer a personalised approach to treating diabetes in the CF population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink